Bridging the Discovery-to-Delivery Gap: Scalable CDMO Insights for Cyclic Peptides

Cyclic peptides are unlocking new frontiers in medicine, offering a powerful strategy to tackle "undruggable" targets that evade traditional small molecules andbiologics. Their constrained conformational structures deliver unparalleled target affinity, specificity, and metabolic stability—empowering researchers to rethink and expand their therapeutic pipelines.

As the global market for mid‑sized molecule therapeutics continues to grow, peptide drug discovery has become an increasingly important field. PeptiDream has emerged as one of the world’s leaders in this space, recognized internationally for its innovative macrocyclic peptide technology and strong global partnerships. To translate these discoveries into scalable, high‑quality peptide APIs, however, industry‑wide manufacturing bottlenecks remained. PeptiStar was established on September 1, 2017, by PeptiDream, Shionogi, and Sekisui Chemical precisely to address this challenge and serve as the strategic CDMO enabling the practical implementation of next‑generation peptide therapeutics.

Today, integrating cyclic peptides into your R&D strategy is no longer just a challenging concept—it is a fully realizable pathway. By partnering with us and exploring our diverse portfolio, you can confidently turn complex peptide designs into scalable clinical realities.